| Eligibility |
Inclusion Criteria:
- Participants who are overtly healthy as determined by medical evaluation including
medical history, physical examination, laboratory tests and cardiac monitoring
[12-lead Electrocardiogram (ECGs)]
- Between 18 and 65 years of age inclusive, at the time of signing the informed consent
- Body weight within the range 45 - 100 kilograms (kg) and body mass index (BMI) within
the range 18-32 kilogram/meter square (kg/m^2) (inclusive)
- A female participant is eligible to participate if she is not pregnant or
breastfeeding, and one of the following conditions applies:
- Is a woman of non-childbearing potential (WONCBP) OR
- Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is
highly effective [with a failure rate of less than 1 percent (<1%) per year], with low
user dependency
- Capable of giving signed informed consent
- Participants of Japanese ancestry are eligible based on meeting all of the following:
- Healthy male and female participants born in Japan
- Descendants of four ethnic Japanese grandparents and two ethnic Japanese parents
- Have lived outside Japan for less than 10 years at the time of screening
- Chinese participants are eligible based on meeting all of the following:
- Healthy male and female participants born in mainland China, Hong Kong, Macau or
Taiwan
- Descendants of four ethnic Chinese grandparents and two ethnic Chinese parents
- Have lived outside mainland China, Hong Kong, Macau or Taiwan for less than 10 years
at the time of screening
- Participants of Caucasian/European ancestry are eligible if they self-identify to be
of Caucasian/European ancestry and have 2 parents of Caucasian/European ancestry and 4
grandparents of Caucasian/European ancestry
Exclusion Criteria:
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
endocrine, hematological, immunological, metabolic, musculoskeletal or neurological
disorders capable of significantly altering the absorption, metabolism, or elimination
of drugs; constituting a risk when taking the study intervention; or interfering with
the interpretation of data
- Personal or family history of cardiomyopathy
- Known varicella, herpes zoster, or other severe viral infection within 6 weeks of
anticipated dosing on Day 1. Or history of recurrent herpes reactivation in the past 2
years
- Evidence of active or latent tuberculosis (TB) as documented by medical history,
examination, and TB testing with a positive (not indeterminate) QuantiFERON test
- History or evidence of clinically significant multiple or severe drug allergies,
intolerance to topical corticosteroids, or severe post-treatment hypersensitivity
reactions (including, but not limited to, anaphylaxis, erythema multiforme major,
linear immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative
dermatitis)
- Lymphoma, leukemia, or any malignancy except for basal cell carcinomas of the skin
that have been resected with no evidence of metastatic disease for 5 years
- Alanine transaminase (ALT) greater than (>) 1.5x upper limit of normal (ULN)
- Total bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35%)
- Current or chronic history of liver disease or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones or previous
uncomplicated cholecystectomy more than 3 months ago)
- Corrected QT using Bazett's formula (QTcB) (Bazett) or Corrected QT using Fridericia's
formula (QTcF) (Fridericia) interval >450 milli second (msec)
- History of Stevens Johnson Syndrome
- Known immunodeficiency
- Previous or current history of bleeding diathesis
- Intended use of over the counter or prescription medication including herbal
medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or
five half-lives (whichever is longer) prior to dosing until final follow-up visit
- Live vaccine(s) or plans to receive such vaccines within 2 months of dosing until
final follow-up visit
- Participation in the study would result in loss of blood or blood products in excess
of 500 milli liter (mL) within 3 months
- Current enrollment or past participation in any other clinical study involving an
investigational study intervention or any other type of medical research within the
last 30 days, 5 half-lives or twice the duration of the known
pharmacological/biological effect from the last dosing before dosing day in the
current study
- Coronavirus strain 19 (COVID-19) (severe acute respiratory syndrome - Coronavirus-2
(SARS CoV-2)):
- Has had COVID-19 infection within 4 weeks of the initial screening visit
- Positive coronavirus test (COVID-19: SARS-CoV-2 Polymerase chain reaction (PCR) or
rapid antigen test) at initial screening
- Signs and symptoms suggestive of COVID-19 (i.e., fever, cough, etc.) within 14 days of
initial screening Known COVID-19-positive contacts within 14 days of initial
Screening, at any time during the Screening Period, or within 14 days of dosing on Day
1
- Active substance abuse or a history of substance abuse within 6 months prior to the
initial Screening visit. Substance abuse including cannabis is also prohibited during
the study
|
